Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below.
Akcea Therapeutics a été racheté par Ionis Pharmaceuticals. Pour des nouvelles et des informations continues sur Akcea Therapeutics, veuillez visiter ionispharma.com. Vous êtes redirigé, veuillez patienter. Si vous n'avez pas été redirigé depuis 30 secondes, veuillez cliquer sur le bouton ci-dessous.
World-class scientific experts guide Akcea development programs.
John Kastelein, MC, PhD, FESC
Professor of Medicine, Chairman of the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam
Dr. John Kastelein is a recognized world leader in studies focused on the significance of lipoprotein metabolism in the development of atherosclerotic vascular disease. Dr. Kastelein’s current research interests focus on the etiology, diagnosis, prevention, and treatment of hypertriglyceridemia, hypercholesterolemia, and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published more than 740 research papers in peer-reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA, and Circulation. His Hirsch index is 82; and his total citations are more than 23,000.
Joseph Witztum, MD
Professor of Medicine, Department of Medicine and Director, Atherosclerosis Research Group, University of California, San Diego
Dr. Joseph Witztum is a Distinguished Professor of Medicine in Endocrinology/Metabolism at the University of California – San Diego in La Jolla, where he continues to see patients in his Lipid Research Clinic. He is internationally recognized for his research into the pathogenesis of atherosclerosis and directs a group of investigators studying both basic mechanisms, as well as novel approaches to diagnosis and therapy of atherosclerosis in humans. He pioneered the concept of the role of oxidized LDL (OxLDL) in the pathogenesis of atherosclerosis, studies that place OxLDL central to an understanding of atherogenesis. Besides his basic research studies, he has remained active in clinical lipidology and has been a member of national consensus panels. Dr Witztum has published more than 400 scientific manuscripts and papers and is an ISI Most Highly Cited Author. He has been an Associate Editor of multiple journals and is currently Editor-in-Chief of the Journal of Lipid Research.
Sotirios (Sam) Tsimikas, MD
Professor of Medicine and Director of Vascular Medicine at the University of California, San Diego, Vice President, Clinical Development, Ionis Pharmaceutical, Inc.
Dr. Sam Tsimikas earned his medical degree in 1988 from the University of Massachusetts Medical School and completed his Internal Medicine training at the University of Massachusetts Medical Center in 1991. He completed separate fellowships in Cardiovascular Disease, Atherosclerosis, and Interventional Cardiology at the University of California, San Diego, from 1992-1997. Dr. Tsimikas’ clinical interests are focused in his role as Director of the Vascular Medicine Program that encompasses treating a wide variety of patients in the continuum of high-risk primary prevention to endovascular intervention. Areas of interest include evaluating and treating patients with elevated Lp(a) levels and percutaneous coronary and peripheral interventions. This program also functions as a key teaching venue for general and interventional cardiology fellows. Dr. Tsimikas has published more than 195 articles and book chapters, including in NEJM, Cell, Nature, JACC, JCI, Circulation, Circulation Research, ATVB, and EHJ. He is Fellow of the American College of Cardiology, the American Heart Association, and the Society for Cardiac Angiography and Interventions.
Rosanne Crooke, PhD
Vice President, Cardiovascular Disease Antisense Drug Discovery, Ionis Pharmaceuticals
Under Dr. Rosanne Crooke’s leadership, the Cardiovascular (CV) / Metabolic research program has demonstrated that antisense technology can be used to create multiple drugs to treat CV and metabolic diseases. The vast pipeline of drugs created by this program include Kynamro, an antisense inhibitor to human apoB-100 that is approved for the treatment of HoFH and is completing registration studies in HeFH. Dr. Crooke received her PhD at the University of Pennsylvania in 1986 and has progressed to steadily more senior positions at Ionis. She is an expert in RNA-targeted therapeutics and cardiovascular and metabolic drug discovery. She has authored more than 85 scientific publications and is an inventor on nearly 70 patents and patent applications.